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T
he fact that cannabis is the most widely used illicit 
drug has motivated a great deal of research aimed 
at understanding how it produces its psychoactive 
effects. Here I use the term psychoactive to describe the 
mild euphoria, altered perceptions, sense of relaxation, and 
sociability that often, but not always, accompany recreational 
cannabis use. Despite the difﬁ  culties inherent in working 
with lipophilic cannabinoids such as ∆9-tetrahydrocannabinol 
(THC), which is the primary psychoactive component of 
cannabis, our understanding of the mechanism of action 
of these compounds at the cellular level has increased 
dramatically over the past 20 years. However, a complete 
understanding of how cannabis elicits its psychoactive effects 
would include an appreciation of its actions at the cellular 
and network level as well as an identiﬁ  cation of the neural 
circuits perturbed.  The cannabinoid ﬁ  eld has now matured 
to the point where investigators can begin to relate the 
cellular mechanisms of THC action to the behavioral effects 
of cannabis.
Research during the past 20 years has led to the 
discovery of the endocannabinoid system, or ECS. The 
ECS is composed of cannabinoid receptors, endogenous 
cannabinoids (endocannabinoids), and the enzymes that 
synthesize and degrade the endocannabinoids [1,2]. There 
are two well-characterized cannabinoid receptors, CB1 
and CB2, both of which are G protein-coupled receptors 
(GPCRs) [3]. I will focus on CB1, which appears to mediate 
most of the psychoactive effects of cannabis. Binding, in 
situ hybridization, and immunocytochemical studies reveal 
a striking pattern of CB1 expression. The receptor is one of 
the most abundantly expressed GPCRs in the brain and is 
particularly enriched in the cortex, amygdala, hippocampus, 
basal ganglia, and cerebellum [4,5]. CB1 receptors are highly 
expressed on axons and axon terminals, where they are well 
positioned to modulate neurotransmission [6]. Indeed, 
endocannabinoids produced by neurons or glia mediate 
several forms of transient and persistent synaptic plasticity 
[7]. In addition to these synaptic actions, the activation of 
somatic CB1 receptors inhibits neuronal excitability in some 
forebrain and cerebellar neurons [8,9]. Given the widespread 
role of CB1 receptors and endocannabinoids in eliciting or 
shaping neuronal plasticity, it is reasonable to speculate that 
THC and other cannabinoids produce their psychoactive 
effects by perturbing endocannabinoid-mediated plasticity or 
neuronal excitability.
A fundamental issue when studying the mechanism of 
action of psychoactive drugs is choosing an animal model 
that best represents the effects of the drug in humans. When 
knockout mice are used, this question becomes choosing 
the appropriate mouse model. Of course, before a model 
is chosen, the particular effect(s) being modeled need to 
be determined. In the case of commonly abused drugs, 
these effects may range from therapeutic (e.g., analgesia) 
to subjective (e.g., relaxation, altered perception, etc.) to 
reinforcing (e.g., self-administration, craving, etc.) actions of 
the drug. Reliable models for some of these behaviors—e.g., 
analgesia, self-administration, relapse, sensitization, etc.—
have been developed, but models for more subjective effects 
such as hallucinations and subtle alterations in perception 
have been more difﬁ  cult to establish. Indeed, one might 
argue that rodents won’t experience some of these subjective 
effects, so efforts in this direction may be futile. Also 
complicating model design and choice is that many drugs of 
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Figure 1. CB1 Expression Levels Vary Widely in the Mouse 
Hippocampal Formation.
In cortex, CB1 mRNA is highly expressed in a very restricted set of 
interneurons and more moderately expressed in a broader population 
of principal neurons. A representative coronal section through the 
hippocampal formation of mouse brain is shown. Nonradioactive in 
situ hybridization was used to identify CB1 mRNA-containing cells. 
The very highest levels (darkest red) are found in a restricted subset of 
cells (arrowheads) that are distributed throughout the hippocampal 
formation. Other studies have shown these to be CCK-containing 
GABAergic interneurons. Intermediate levels (light pink) are found in 
the principal neurons of CA1 (arrows) and CA3. Dentate granule cells 
(asterisks) do not express CB1 mRNA and provide a measure of the 
background inherent in this technique. Nuclei are identiﬁ  ed by toluidine 
blue counterstaining. This general pattern of expression is recapitulated 
throughout the neocortex and amygdala. mo, molecular layer; po, 
polymorphic layer; sg, granule cell layer; slm, stratum lacunosum; so, 
stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. 
(Original image provided by Martin Häring.)
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abuse, including cannabis, elicit biphasic effects in humans 
where at a low dose (or in some subjects), positive effects 
dominate, but at higher doses, the opposite is observed. For 
example, low doses of THC are rewarding, while higher doses 
are aversive, and still higher doses cause motor impairment 
that obscures any rewarding or aversive effects [10]. Thus, it 
is important that full dose-response studies are conducted in 
the chosen animal model.
Animal models for the behavioral effects of cannabinoids 
have primarily focused on prediction of cannabis-like activity, 
drug discrimination, and memory disruption. The dog static 
ataxia test is historically signiﬁ  cant. Studies using this model 
were among the ﬁ  rst to strongly suggest that THC produced 
behavioral effects via a receptor, rather than by nonspeciﬁ  c 
membrane interactions. The administration of cannabinoid 
compounds to a dog causes the dog to weave back and forth 
while remaining in one place; the term “static ataxia” was 
coined to describe this peculiar collection of behaviors. 
Compounds that produced static ataxia in the dog had a high 
likelihood of eliciting cannabis-like psychoactivity in humans, 
and it was possible to develop a structure-activity relationship 
for cannabinoids using this test [11]. These ﬁ  ndings, plus the 
observation that static ataxia is blocked by the CB1 receptor 
antagonist SR141716 (rimonabant), strongly suggest that 
both are mediated by CB1 receptors [12]. However, as with 
most animal behavioral responses to cannabinoids, these 
observations do not necessarily imply (indeed it is highly 
unlikely) that the neural circuits underlying static ataxia are 
the same as those producing psychoactivity in humans.
The dog static ataxia test appears accurate in predicting 
cannabis-like psychoactivity of a compound; however, it and 
other tests such as drug discrimination and memory tasks are 
either ﬁ  nancially costly or require time-consuming subject 
training to perform, which are drawbacks limiting their 
widespread use. The shortcomings of the available models 
for screening cannabinoid-like compounds prompted a 
continuing search for alternatives and led to the development 
of the mouse “tetrad” in the mid-1980s by Billy Martin’s group 
[13]. The tetrad consists of four individual tests: analgesia 
(typically by tail withdrawal or ﬂ  ick), sedation, catalepsy, 
and hypothermia. Although none of these tests individually 
is predictive of cannabis-like activity, the presence of the 
four responses often, but not invariably [14], correlates with 
a drug having either cannabis-like psychoactivity and/or 
agonist activity at CB1 receptors. A distinct advantage of the 
tetrad is that its components can be measured sequentially 
after drug administration, greatly simplifying behavioral 
assay design. Because of its robustness and relative ease of 
use, the tetrad has assumed a place of central importance in 
behavioral assays of cannabinoid action.
A large number of studies demonstrate that THC or potent 
synthetic cannabinoids produce the tetrad by activating CB1 
receptors. The most compelling of these include antagonism 
of the tetrad by CB1 receptor antagonists such as rimonabant 
[15] and its absence in CB1 receptor knockout mice [16]. 
Despite the tetrad’s importance for studying the behavioral 
pharmacology of cannabinoids, little is known about which 
neurons underlie its components. It is tempting to speculate 
that the neurons expressing the highest levels of cannabinoid 
receptors might be important for producing the tetrad. 
In the cortex, amygdala, and hippocampus, CB1 is highly 
expressed in a subclass of large-diameter, cholecystokinin 
(CCK)-positive GABAergic interneurons (those that release 
γ aminobutyric acid), for example, [17]. However, CB1 
receptors are also extensively expressed at lower levels in a 
wide variety of neurons, including glutamatergic principal 
cells throughout the forebrain [18–20]. This is illustrated for 
the hippocampal formation in Figure 1. Thus, understanding 
how THC produces the behaviors measured in the tetrad 
depends on determining which neurons are involved.
The paper by Monory and colleagues in this issue of PLoS 
Biology elegantly addresses this problem using mice with CB1 
receptors “knocked out” of speciﬁ  c populations of neurons 
[21]. These investigators have generated mice whose CB1 
gene (Cnr1) is ﬂ  anked by loxP sites (“ﬂ  oxed”) to precisely 
delete CB1 receptors from certain classes of neurons. This 
control is possible because the DNA sequence between two 
loxP sites will be excised by the DNA recombinase, Cre. By 
expressing Cre under the control of cell-speciﬁ  c promoters, 
CB1 receptors can be deleted from restricted populations 
of cells. In their study, Monory and colleagues crossed these 
ﬂ  oxed mice with mice carrying Cre recombinase under the 
control of speciﬁ  c promoters, which are active only in certain 
neurons. This caused the deletion of CB1 receptors from 
selected neuronal populations, which was determined by 
the particular promoter. This group and their collaborators 
have previously used this approach to demonstrate the 
importance of CB1 expression in glutamatergic neurons 
in the neuroprotective effects of endocannabinoids in a 
seizure model [22] as well as to deﬁ  ne the signiﬁ  cant role of 
peripherally expressed CB1 receptors in analgesic responses 
to cannabinoids [23].
For the present study, in addition to the global knockout 
of CB1, the researchers used four mouse lines that lacked 
CB1 in GABAergic neurons, two populations of glutamatergic 
neurons, or dopamine D1 receptor-expressing neurons. 
Interestingly, the loss of CB1 from GABAergic neurons, a 
maneuver that strongly decreases overall CB1 expression 
and ablates some forms of CB1 receptor-mediated synaptic 
plasticity [22], had no signiﬁ  cant effect on any of the four 
components of the tetrad. In contrast, the deletion of CB1 
from principal glutamatergic neurons strongly attenuated 
the four components of the tetrad. Within the limitations of 
this experimental approach (e.g., compensation that may 
occur due to developmental loss of CB receptors), these 
results strongly suggest that CB1 expression on glutamatergic 
neurons is crucial in producing all of the behavioral 
responses observed in the tetrad, whereas CB1 receptors on 
GABAergic neurons play little if any role in tetrad responses. 
Thus, this study, while answering one important question, 
raises another equally fascinating one: What role (if any) do 
the high levels of CB1 receptor found on the CCK-positive 
GABAergic interneurons play in the behavioral responses to 
THC and cannabis?
What directions might future research using genetically 
engineered mice take to advance our understanding of 
the psychoactive effects of cannabis? The most frequently 
described subjective effects of cannabis intoxication in 
humans include altered perception (particularly in the 
passage of time), a sense of relaxation, sociability, and a 
variety of cognitive effects [24]. A challenge for the ﬁ  eld 
will be to take or develop well-validated mouse behavioral 
models for these subjective effects and apply them to mice 
lacking CB1 receptors in speciﬁ  c neuronal populations 
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and treated with THC. Some examples of this would be 
region-dependent memory tests (particularly those involving 
the hippocampus as well as extinction of memories), 
tests of anxiety, and drug discrimination. This line of 
investigation should help to elucidate the role of these 
neuronal populations in behaviorally complex actions of 
cannabis. These studies will powerfully complement those 
where cannabinoids or their antagonists are microinjected 
into discrete brain regions to identify the anatomical loci 
that underlie speciﬁ  c behavioral responses to THC. While 
experiments similar to those described in the current 
work are difﬁ  cult to conduct, including the breeding 
and characterization of the mouse lines as well as the 
appropriate performance of behavioral assays, their careful 
implementation will help deﬁ  ne the neural substrate(s) for 
the psychoactive effects of cannabis that are particularly 
prominent during human consumption.  
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